This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Technology / Risen Pharma initiates RP902 Phase 2
Tech clinical trial

Risen Pharma initiates RP902 Phase 2

Analysis based on 7 articles · First reported May 19, 2026 · Last updated May 22, 2026

Sentiment
60
Attention
4
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The initiation of a Phase 2 clinical trial for RP902 by Risen Pharma could positively impact the biotechnology and pharmaceutical sectors, particularly companies focused on neurodegenerative diseases. Success in this trial could lead to significant stock price appreciation for Risen Pharma and attract further investment into Alzheimer's research.

Biotechnology Pharmaceuticals
Event Summary

Risen Pharma, a clinical-stage biotech company, announced the initiation of a Phase 2 clinical study in China for RP902. RP902 is an oral small-molecule drug designed to treat mild cognitive impairment due to Alzheimer s disease, specifically targeting apolipoprotein E ε4 (ApoE ε4) carriers. The multicenter, randomized, double-blind, placebo-controlled trial will evaluate the safety and efficacy of RP902, with the primary endpoint being the change in the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) score. Professors Tang Yi and Yongjun Wang are co-leading the study. This development addresses a significant unmet medical need in China, where Alzheimer s disease prevalence is high.

Entities Involved
priv
Risen Pharma
Risen Pharma initiated a Phase 2 clinical trial for its drug RP902, which could significantly advance its pipeline and market position in Alzheimer s disease treatment.
Importance 100.0 Sentiment 70.0
priv
Risen Shanghai Pharma Tech Co., Ltd.
Risen Shanghai Pharma Tech Co., Ltd. is the parent company of Risen Pharma, which announced the initiation of the Phase 2 clinical trial for RP902.
Importance 100.0 Sentiment 70.0
oth
RP902
RP902 is the oral small-molecule drug undergoing a Phase 2 clinical trial for mild cognitive impairment due to Alzheimer s disease, representing a key asset for Risen Pharma.
Importance 90.0 Sentiment 65.0
per
Tang Yi
Professor Tang Yi is co-leading the Phase 2 clinical trial, providing scientific expertise and credibility to the study.
Importance 20.0 Sentiment 0.0
per
Yongjun Wang
Professor Yongjun Wang is co-leading the Phase 2 clinical trial, contributing to its scientific direction and execution.
Importance 20.0 Sentiment 0.0
oth
Capital Medical University
Capital Medical University is affiliated with the hospitals where the clinical trial co-leads are based, lending academic support to the study.
Importance 10.0 Sentiment 0.0
oth
Beijing Tiantan Hospital
Beijing Tiantan Hospital, affiliated with Capital Medical University, is where Professor Yongjun Wang is based, participating in the clinical trial.
Importance 10.0 Sentiment 0.0
cnt
China
Importance 0.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.